Alfred Garfall

1 month ago | targetedonc.com | Jordyn Sava |Alfred Garfall

In this episode of Targeted Talks, Alfred L. Garfall, MD, director of Autologous Hematopoietic Stem Cell Transplantation and section chief of Myeloma and Hematology-Oncology at Penn Medicine, discusses the phase 2 BMT CTN 1902 trial (NCT05032820) of idecabtagene vicleucel (ide-cel; Abecma), a study focused on patients with multiple myeloma who had a suboptimal response to first-line therapy, including autologous hematopoietic cell transplant and lenalidomide (Revlimid) maintenance.

1 month ago | cgtlive.com | Alfred Garfall |Noah Stansfield

At the 2025 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Honolulu, Hawaii, February 12 to 15, 2025, interim data were presented from the phase 2 BMT CTN 1902 clinical trial (NCT05032820), which is evaluating Bristol Myers Squibb and 2seventy bio's idecabtagene vicleucel (ide-cel, marketed as Abecma), an FDA-approved chimeric antigen receptor T-cell (CAR-T) therapy, for the treatment of patients with multiple myeloma (MM) who had a suboptimal...

Oct 20, 2024 | nature.com | Nizar Bahlis |Luciano Costa |Maria-Victoria Mateos |Ajay K. Nooka |Aurore Perrot |Alfred Garfall | +1 more

Dear Editor,The risk of infection in patients with multiple myeloma (MM) is high, particularly for those with relapsed/refractory MM (RRMM), who typically exhibit substantial immune dysfunction due to multiple prior therapies as well as MM itself [1, 2]. The recent COVID-19 pandemic had an impact on patients with MM compared with non-MM patients, including a higher risk of infection, a higher excess mortality rate, and decreased survival in 2020 compared with 2019 [3].

Jul 24, 2024 | ajmc.com | Alfred Garfall

OpinionVideoJuly 24, 2024Author(s):Alfred L. Garfall, MD, discusses his hopes for the future treatment landscape of multiple myeloma. Video content above is prompted by the following questions:Please discuss any other data in multiple myeloma released at ASCO 2024 that you find noteworthy to share with colleagues. Outside of ASCO 2024, what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?

Jul 19, 2024 | ajmc.com | Alfred Garfall

Video content above is prompted by the following questions:Discuss the data presented at ASCO 2024 on the DREAMM-8 study (NCT04484623) of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in patients with relapsed/refractory multiple myeloma (RRMM). (Abstract)What was the objective of this study? How was this study designed/what methodology was used? What results were presented?